

**PRESCRIBED DRUGS IMMUNIZATION FEE SCHEDULE  
COVERAGE INFORMATION AND SPECIAL CONSIDERATIONS**

**General Immunization Billing Requirements:**

Florida Medicaid providers administering vaccines to Florida Medicaid recipients enrolled in the fee-for-service delivery system must submit two Current Procedural Terminology (CPT) codes on the claim for reimbursement of administration from Florida Medicaid: (1)The vaccine product code AND (2)The vaccine administration code. A corresponding administration code must be submitted for each vaccine administered during the same visit on the claim form.

**Vaccines for Children (VFC) Program Reimbursement Guidelines:**

Florida Medicaid providers receiving vaccine products through the Vaccine for Children (VFC) Program for fee-for-service recipients 0 through 18 years of age are reimbursed for the administration of the vaccine(s) only. Vaccine product codes are reimbursed at \$0.00. Vaccine administration codes are reimbursed in accordance with rates established on this fee schedule.

**MediKids Guidelines:**

MediKids enrolls children one through four years of age. MediKids enrollees are eligible for all immunizations recommended by the Advisory Committee on Immunization Practices (ACIP) for this age group. However, MediKids enrollees are not eligible to receive products provided through the VFC Program. Florida Medicaid providers who administer vaccines to MediKids enrollees are to be reimbursed for the vaccine products and administration services by the enrollee's Managed Care Plan.

**Mid-level Practitioner Reimbursement:**

Administration services are reimbursed at 80% of the maximum fee when performed by an advanced practice registered nurse (APRN), physician's assistant (PA), or registered pharmacist (RPh). Vaccine product codes are reimbursed in accordance with rates established on this fee schedule.

**COVID-19 Vaccine Billing and Reimbursement Guidelines:**

Florida Medicaid providers administering COVID-19 vaccines to Florida Medicaid recipients enrolled in the fee-for-service delivery system must submit the CPT code for the specific vaccine product in conjunction with the COVID-19-specific vaccine administration code on the claim for reimbursement. The product CPT code and the COVID-19 administration code must be submitted for each vaccine dose administered on the claim form.

**MPox Vaccine Billing and Reimbursement Guidelines:**

Jynneos is eligible for the listed reimbursement rate for dates of service beginning on 08/01/2024.

**\*Influenza Vaccine Billing and Reimbursement Guidelines:**

CPT codes for quadrivalent formulations of the Influenza vaccine (2023 - 2024 Flu Season) are to be used for claims with dates of service through 04/30/2024. CPT codes for trivalent formulations of the Influenza vaccine (2024-2025 Flu Season) are eligible for claim reimbursement for dates of service beginning on 05/01/2024. Vaccine product codes are reimbursed in accordance with rates established on this fee schedule in conjunction with the billing and reimbursement guidelines stated here regarding date of service for submitted claims.

*^ Respiratory Syncytial Virus monoclonal antibody codes have specific administration codes that must be billed together.*

**PRESCRIBED DRUGS IMMUNIZATION FEE SCHEDULE**

**EFFECTIVE: JANUARY 1, 2024**

| CPT Code                                    | Modifier | Description   | Units | Age (Years) | MaxFee |
|---|----------|---|-------|-------------|--------|
| <b>GENERAL VACCINE ADMINISTRATION CODES</b> |          |   |       |             |        |
| 90460                                       |          | Administration of first vaccine or toxoid component through 18 years of age, with counseling  |       | 0-18        | 10.00  |
| 90471                                       |          | Administration of one vaccine, single or combination vaccine/toxoid. (percutaneous, intradermal, subcutaneous or intramuscular)             |       | 0+          | 10.00  |
| 90472                                       |          | Administration of each additional vaccine, single or combination vaccine/toxoid. (percutaneous, intradermal, subcutaneous or intramuscular) |       | 0+          | 10.00  |
| 90473                                       |          | Immunization administration by intranasal or oral route of one vaccine, single or combination vaccine/toxoid.                               |       | 0+          | 10.00  |

**PRESCRIBED DRUGS IMMUNIZATION FEE SCHEDULE**

**EFFECTIVE: JANUARY 1, 2024**

| CPT Code   | Modifier | Description   | Units | Age (Years) | MaxFee |
|--|----------|---|-------|-------------|--------|
| 90474  |          | Administration of each additional intranasal or oral vaccine (single or combination vaccine/toxoid)   |       | 0+          | 10.00  |
| <b>MPOX</b>  |          |   |       |             |        |
| 90611  |          | Smallpox and monkeypox vaccine, attenuated vaccinia virus, live, non-replicating, preservative free, 0.5 mL dosage, suspension, for subcutaneous use [ <i>Jynneos</i> ] | 1     | 18+         | 270.00 |
| <b>HEPATITIS B</b>   |          |   |       |             |        |
| 90739  |          | Hepatitis B vaccine (HepB), CpG-adjuvanted, adult dosage, 2 dose or 4 dose schedule for intramuscular use [ <i>Heplisav-B</i> ]   | 1     | 18          | 0.00   |
| 90739  | HA       | Hepatitis B vaccine (HepB), CpG-adjuvanted, adult dosage, 2 dose or 4 dose schedule for intramuscular use [ <i>Heplisav-B</i> ]   | 1     | 19+         | 140.60 |
| 90740  |          | Hepatitis B vaccine (HepB), dialysis or immunosuppressed patient dosage, 3 dose schedule, for intramuscular use [ <i>Recombivax HB - Dialysis formulation</i> ]         | 1     | 18+         | 158.15 |
| 90743  |          | Hepatitis B vaccine (HepB), adolescent, 2 dose schedule, for intramuscular use [ <i>Recombivax-B-ADULT</i> ; <i>Engerix-B-ADULT</i> ]                                   | 1     | 11 - 15     | 0.00   |
| 90744  |          | Hepatitis B vaccine (HepB), pediatric/adolescent dosage, 3 dose schedule, for intramuscular use [ <i>Recombivax-PEDS</i> ; <i>Engerix-B-PEDS</i> ]                      | 1     | 0-18        | 0.00   |
| 90746  |          | Hepatitis B vaccine (HepB), adult dosage, 3 dose schedule for intramuscular use [ <i>Recombivax-B-ADULT</i> ; <i>Engerix-B-ADULT</i> ]                                  | 1     | 19+         | 68.16  |
| 90759  |          | Hepatitis B vaccine (HepB), 3-antigen (S, Pre-S1, Pre-S2), 10 mcg dosage, 3 dose schedule, for intramuscular use [ <i>PreHevbrio</i> ]                                  | 1     | 18          | 0.00   |
| 90759  | HA       | Hepatitis B vaccine (HepB), 3-antigen (S, Pre-S1, Pre-S2), 10 mcg dosage, 3 dose schedule, for intramuscular use [ <i>PreHevbrio</i> ]                                  | 1     | 19+         | 65.50  |
| <b>ROTAVIRUS (RV)</b>  |          |   |       |             |        |
| 90680  |          | Rotavirus vaccine, pentavalent [RV5], 3 dose schedule, live, for oral use [ <i>RotaTeq</i> ]  | 1     | 0-1         | 0.00   |
| 90681  |          | Rotavirus vaccine, human, attenuated [RV1], 2 dose schedule, live, for oral use [ <i>Rotarix</i> ]  | 1     | 0-1         | 0.00   |
| <b>DIPHTHERIA/TETANUS/ACELLULAR PERTUSSIS AND COMBINATIONS</b> |          |   |       |             |        |
| <b><i>Diphtheria, Tetanus, &amp; Pertussis (DTaP)</i></b>      |          |   |       |             |        |
| 90700  |          | Diphtheria, tetanus, and acellular pertussis (whooping cough) (DTaP), intramuscular [ <i>Daptacel</i> ; <i>Infanrix</i> ]   | 1     | 0-6         | 0.00   |
| <b><i>Diphtheria &amp; Tetanus (DT)</i></b>                    |          |   |       |             |        |
| 90702  |          | Diphtheria and tetanus toxoids, intramuscular [ <i>DT</i> ]   | 1     | 0-7         | 0.00   |
| <b><i>Tetanus &amp; Diphtheria (Td)</i></b>                    |          |   |       |             |        |
| 90714  |          | Tetanus and diphtheria toxoids, intramuscular [ <i>Tenivac</i> , <i>TDVAX</i> ]   | 1     | 7 - 18      | 0.00   |
| 90714  | HA       | Tetanus and diphtheria toxoids, intramuscular [ <i>Tenivac</i> , <i>TDVAX</i> ]   | 1     | 19+         | 32.55  |
| <b><i>Tetanus, Diphtheria, &amp; Pertussis (Tdap)</i></b>      |          |   |       |             |        |
| 90715  |          | Tetanus, diphtheria toxoids, and acellular pertussis (whooping cough) (Tdap), intramuscular [ <i>Boostrix</i> , <i>Adacel</i> ]   | 1     | 7 - 18      | 0.00   |
| 90715  | HA       | Tetanus, diphtheria toxoids, and acellular pertussis (whooping cough) (Tdap), intramuscular [ <i>Boostrix</i> , <i>Adacel</i> ]   | 1     | 19+         | 47.61  |
| <b><i>Diphtheria &amp; Tetanus Combinations</i></b>            |          |   |       |             |        |
| 90696  |          | Diphtheria, tetanus toxoids, acellular pertussis (whooping cough), and polio (DTaP-IPV), intramuscular [ <i>Quadracel</i> ; <i>Kinrix</i> ]                             | 1     | 4 - 6       | 0.00   |

**PRESCRIBED DRUGS IMMUNIZATION FEE SCHEDULE**

**EFFECTIVE: JANUARY 1, 2024**

| <b>CPT Code</b>                            | <b>Modifier</b> | <b>Description</b>   | <b>Units</b> | <b>Age (Years)</b> | <b>MaxFee</b> |
|--|-----------------|--|--------------|--------------------|---------------|
| 90697                                      |                 | Diphtheria, tetanus toxoids, acellular pertussis (whooping cough), polio, Haemophilus influenza type b and hepatitis B (DTaP-IPV-HIB-HEPB), intramuscular [ <i>Vaxelis</i> ] | 1            | 0-4                | 0.00          |
| 90698                                      |                 | Diphtheria, tetanus toxoids, acellular pertussis (whooping cough), Haemophilus influenza type B and polio (DTaP-HIB-IPV), intramuscular [ <i>Pentacel</i> ]                  | 1            | 0-4                | 0.00          |
| 90723                                      |                 | Diphtheria, tetanus toxoids, acellular pertussis (whooping cough), Hepatitis B, and polio (DTaP-HepB-IPV), intramuscular [ <i>Pediarix</i> ]                                 | 1            | 0-6                | 0.00          |
| <b>HAEMOPHILUS INFLUENZAE TYPE B (Hib)</b> |                 |  |              |                    |               |
| 90647                                      |                 | Haemophilus influenzae B (3 dose schedule) injection into muscle [ <i>PedvaxHIB</i> ]  | 1            | 0-5                | 0.00          |
| 90648                                      |                 | Haemophilus influenzae B (4 dose schedule) injection into muscle [ <i>ActHIB; Hiberix</i> ]  | 1            | 0-5                | 0.00          |
| <b>PNEUMOCOCCAL</b>                        |                 |  |              |                    |               |
| 90670                                      |                 | Pneumococcal conjugate 13 valent, intramuscular [ <i>Prevnar 13</i> ]  | 1            | 0-18               | 0.00          |
| 90671                                      |                 | Pneumococcal Congugate Vaccine 15 valent, intramuscular (PCV15) [ <i>Vaxneuvance</i> ]   | 1            | 0-18               | 0.00          |
| 90671                                      | HA              | Pneumococcal Congugate Vaccine 15 valent, intramuscular (PCV15) [ <i>Vaxneuvance</i> ]   | 1            | 19+                | 222.55        |
| 90677                                      |                 | Pneumococcal Congugate Vaccine 20 valent, intramuscular (PCV20) [ <i>Prevnar 20</i> ]  | 1            | 0-18               | 0.00          |
| 90677                                      | HA              | Pneumococcal Congugate Vaccine 20 valent, intramuscular (PCV20) [ <i>Prevnar 20</i> ]  | 1            | 19+                | 261.56        |
| 90732                                      |                 | Pneumococcal polysaccharide 23 valent subcutaneous or intramuscular [ <i>Pneumovax 23</i> ]  | 1            | 2 - 18             | 0.00          |
| 90732                                      | HA              | Pneumococcal polysaccharide 23 valent subcutaneous or intramuscular [ <i>Pneumovax 23</i> ]  | 1            | 19+                | 117.08        |
| <b>INACTIVATED POLIOVIRUS (IPV)</b>        |                 |  |              |                    |               |
| 90713                                      |                 | Polio vaccine, injection beneath the skin or into muscle [ <i>IPOLE</i> ]  | 1            | 0-18               | 0.00          |
| <b>INFLUENZA, 2024 - 2025 SEASON</b>       |                 |  |              |                    |               |
| <b>Influenza (aIV)</b>                     |                 |  |              |                    |               |
| 90653                                      |                 | Influenza vaccine, inactivated (IIV), subunit, adjuvanted, for intramuscular use [ <i>FLUAD</i> ]  | 1            | 65+                | 73.40         |
| <b>Influenza (IIV3)</b>                    |                 |  |              |                    |               |
| 90655                                      |                 | Influenza virus vacine, trivalent (IIV3), split virus, preservative free, 0.25 mL dosage, for intramuscular use [ <i>Fluzone Preservative Free</i> ]*                        | 1            | 0-2                | 0.00          |
| 90656                                      |                 | Influenza virus vaccine, trivalent (IIV3), split virus, preservative free, 0.5 mL dosage, for intramuscular use [ <i>Fluzone Preservative Free</i> ]*                        | 1            | 0-18               | 0.00          |
| 90656                                      | HA              | Influenza virus vaccine, trivalent (IIV3), split virus, preservative free, 0.5 mL dosage, for intramuscular use [ <i>Fluzone Preservative Free</i> ]*                        | 1            | 19+                | 20.25         |
| 90657                                      |                 | Influenza virus vaccine, trivalent (IIV3), split virus, 0.25 mL dosage, for intramuscular use [ <i>Fluzone</i> ]*  | 1            | 0-2                | 0.00          |

**PRESCRIBED DRUGS IMMUNIZATION FEE SCHEDULE**

**EFFECTIVE: JANUARY 1, 2024**

| <b>CPT Code</b>                      | <b>Modifier</b> | <b>Description</b>  | <b>Units</b> | <b>Age (Years)</b> | <b>MaxFee</b> |
|--------------------------------------|-----------------|---|--------------|--------------------|---------------|
| 90658                                |                 | Influenza virus vaccine, trivalent (IIV3), split virus, 0.5 mL dosage, for intramuscular use[Afluria; FluLaval TIV; Fluzone] *  | 1            | 0 - 18             | 0.00          |
| 90658                                | HA              | Influenza virus vaccine, trivalent (IIV3), split virus, 0.5 mL dosage, for intramuscular use [Afluria; Fluzone] *   | 1            | 19+                | 21.14         |
| 90662                                |                 | Influenza virus vaccine (IIV), split virus, preservative free, enhanced immunogenicity via increased antigen content, for intramuscular use [Fluzone High-Dose ]*             | 1            | 65+                | 73.40         |
| <b>Influenza (LAIV3)</b>             |                 |   |              |                    |               |
| 90660                                |                 | Influenza virus vaccine, trivalent, live (LAIV3), for intranasal use[FluMist ]*   | 1            | 2-18               | 0.00          |
| 90660                                | HA              | Influenza virus vaccine, trivalent, live (LAIV3), for intranasal use[FluMist ]*   | 1            | 19+                | 24.70         |
| <b>Influenza (ccIIV3)</b>            |                 |   |              |                    |               |
| 90661                                |                 | Influenza virus vaccine (ccIIV3), derived from cell cultures, subunit, preservative and antibiotic free, 0.5 mL dosage, for intramuscular use [Flucelvax ]                    | 1            | 0 - 18             | 0.00          |
| 90661                                | HA              | Influenza virus vaccine (ccIIV3), derived from cell cultures, subunit, preservative and antibiotic free, 0.5 mL dosage, for intramuscular use [Flucelvax ]                    | 1            | 19+                | 32.45         |
| <b>Influenza (RIV3)</b>              |                 |   |              |                    |               |
| 90673                                |                 | Influenza virus vaccine, trivalent (RIV3), derived from recombinant DNA, hemagglutinin (HA) protein only, preservative and antibiotic free, for intramuscular use [Flublok ]* | 1            | 18                 | 73.40         |
| 90673                                | HA              | Influenza virus vaccine, trivalent (RIV3), derived from recombinant DNA, hemagglutinin (HA) protein only, preservative and antibiotic free, for intramuscular use [Flublok ]* | 1            | 19+                | 73.40         |
| <b>INFLUENZA, 2023 - 2024 SEASON</b> |                 |   |              |                    |               |
| <b>Influenza (IIV4)</b>              |                 |   |              |                    |               |
| 90655                                |                 | Influenza vaccine for administration into muscle, 0.25ml dosage, preservative free*   | 1            | 0-2                | 0.00          |
| 90656                                |                 | Influenza vaccine for administration into muscle, 0.5ml dosage, preservative free*  | 1            | 0 - 18             | 0.00          |
| 90656                                | HA              | Influenza vaccine for administration into muscle, 0.5ml dosage, preservative free*  | 1            | 19+                | 19.76         |
| 90657                                |                 | Influenza vaccine for administration into muscle, 0.25ml dosage*  | 1            | 0-2                | 0.00          |
| 90658                                |                 | Influenza vaccine for administration into muscle, 0.5ml dosage*   | 1            | 0 - 18             | 0.00          |
| 90658                                | HA              | Influenza vaccine for administration into muscle, 0.5ml dosage*   | 1            | 19+                | 19.22         |
| 90685                                |                 | Influenza vaccine, intramuscular administration, 0.25ml dosage, quadrivalent, preservation free*  | 1            | 0-3                | 0             |
| 90686                                |                 | Influenza vaccine, intramuscular administration, 0.5ml dosage, quadrivalent, preservation free*   | 1            | 0 - 18             | 0.00          |
| 90686                                | HA              | Influenza vaccine, intramuscular administration, 0.5ml dosage, quadrivalent, preservation free*   | 1            | 19+                | 19.73         |
| 90687                                |                 | Influenza vaccine intramuscular administration, 0.25ml dosage, quadrivalent*  | 1            | 0-3                | 0.00          |
| 90688                                |                 | Influenza vaccine intramuscular administration, 0.5ml dosage, quadrivalent MDV*   | 1            | 0 - 18             | 0.00          |

| PRESCRIBED DRUGS IMMUNIZATION FEE SCHEDULE |          |   |       |             |        |
|--|----------|---|-------|-------------|--------|
| EFFECTIVE: JANUARY 1, 2024                 |          |   |       |             |        |
| CPT Code                                   | Modifier | Description   | Units | Age (Years) | MaxFee |
| 90688                                      | HA       | Influenza vaccine intramuscular administration, 0.5ml dosage, quadrivalent MDV*   | 1     | 19+         | 18.44  |
| <b>Influenza (LAIV4)</b>                   |          |   |       |             |        |
| 90672                                      |          | Influenza vaccine quadrivalent, nasal administration [ <i>FluMist Quadrivalent</i> ]*   | 1     | 2-18        | 0.00   |
| 90672                                      | HA       | Influenza vaccine quadrivalent, nasal administration [ <i>FluMist Quadrivalent</i> ]*   | 1     | 19-20       | 23.75  |
| <b>Influenza (ccIV4)</b>                   |          |   |       |             |        |
| 90756                                      |          | Influenza vaccine derived from cell cultures, intramuscular, quadrivalent, antibiotic free, 0.5ml*                                      | 1     | 0-18        | 0.00   |
| 90756                                      | HA       | Influenza vaccine derived from cell cultures, intramuscular, quadrivalent, antibiotic free, 0.5ml*                                      | 1     | 19+         | 28.52  |
| 90674                                      |          | Influenza vaccine derived from cell cultures (ccIV4) preservative/antibiotic free 0.5ml intramuscular*                                  | 1     | 0-18        | 0.00   |
| 90674                                      | HA       | Influenza vaccine derived from cell cultures (ccIV4) preservative/antibiotic free 0.5ml intramuscular*                                  | 1     | 19+         | 30.10  |
| <b>Influenza (RIV4)</b>                    |          |   |       |             |        |
| 90682                                      | HA       | Influenza vaccine derived from DNA for injection into muscle, quadrivalent, preservative and antibiotic free*                           | 1     | 18          | 0.00   |
| 90682                                      |          | Influenza vaccine derived from DNA for injection into muscle, quadrivalent, preservative and antibiotic free*                           | 1     | 19+         | 73.40  |
| <b>MEASLES, MUMPS, RUBELLA (MMR)</b>       |          |   |       |             |        |
| <b>MMR</b>                                 |          |   |       |             |        |
| 90707                                      |          | Measles, mumps, and rubella (German measles) injection beneath skin [ <i>M-M-R II; Priorix</i> ]  | 1     | 0-18        | 0.00   |
| 90707                                      | HA       | Measles, mumps, and rubella (German measles) injection beneath skin [ <i>M-M-R II; Priorix</i> ]  | 1     | 19+         | 92.49  |
| <b>MMR/VZV Combination</b>                 |          |   |       |             |        |
| 90710                                      |          | Measles, mumps, rubella (German measles), and varicella (chicken pox) injection beneath skin [ <i>ProQuad</i> ]                         | 1     | 1 - 12      | 0.00   |
| <b>VARICELLA (VAR)</b>                     |          |   |       |             |        |
| 90716                                      |          | Varicella virus (chicken pox) subcutaneous [ <i>Varivax</i> ]   | 1     | 0-18        | 0.00   |
| 90716                                      | HA       | Varicella virus (chicken pox) subcutaneous [ <i>Varivax</i> ]   | 1     | 19+         | 174.32 |
| <b>HEPATITIS A (HepA)</b>                  |          |   |       |             |        |
| 90632                                      |          | Hepatitis A injection into muscle, adult dosage [ <i>Vaqta-ADULT; Havrix-ADULT</i> ]  | 1     | 18          | 0.00   |
| 90632                                      | HA       | Hepatitis A injection into muscle, adult dosage [ <i>Vaqta-ADULT; Havrix-ADULT</i> ]  | 1     | 19+         | 80.92  |
| 90633                                      |          | Hepatitis A (2 dose schedule) injection into muscle, pediatric or adolescent dosage [ <i>Vaqta-PEDS; Havrix-PEDS</i> ]                  | 1     | 0-18        | 0.00   |
| <b>HUMAN PAPILOMAVIRUS (HPV)</b>           |          |   |       |             |        |
| 90651                                      |          | Human papilloma virus Types 6, 11, 16, 18, 31, 33, 45, 52, 58, nonavalent (3 dose schedule) injection into muscle [ <i>Gardasil 9</i> ] | 1     | 9 - 18      | 0.00   |
| 90651                                      | HA       | Human papilloma virus Types 6, 11, 16, 18, 31, 33, 45, 52, 58, nonavalent (3 dose schedule) injection into muscle [ <i>Gardasil 9</i> ] | 1     | 19 - 45     | 287.54 |
| <b>MENINGOCOCCAL</b>                       |          |   |       |             |        |
| <b>Meningococcal Conjugate (MenACWY)</b>   |          |   |       |             |        |

**PRESCRIBED DRUGS IMMUNIZATION FEE SCHEDULE**

**EFFECTIVE: JANUARY 1, 2024**

| <b>CPT Code</b>   | <b>Modifier</b> | <b>Description</b>  | <b>Units</b> | <b>Age (Years)</b>     | <b>MaxFee</b> |
|---|-----------------|---|--------------|------------------------|---------------|
| 90619   |                 | Meningococcal conjugate vaccine, serogroups A, C, W, Y, quadrivalent, tetanus toxoid carrier (MenACWY-TT) for injection into muscle [MenQuadfi]                             | 1            | 2-18                   | 0.00          |
| 90619   | HA              | Meningococcal conjugate vaccine, serogroups A, C, W, Y, quadrivalent, tetanus toxoid carrier (MenACWY-TT) for injection into muscle [MenQuadfi]                             | 1            | 19+                    | 166.98        |
| 90734   |                 | Meningococcal conjugate vaccine, serogroups A, C, W, Y, quadrivalent, diphtheria toxoid carrier (MenACWY-D) or CRM197 carrier (MenACWY-CRM), for intramuscular use [Menveo] | 1            | 0-18                   | 0.00          |
| 90734   | HA              | Meningococcal conjugate vaccine, serogroups A, C, W, Y, quadrivalent, diphtheria toxoid carrier (MenACWY-D) or CRM197 carrier (MenACWY-CRM), for intramuscular use [Menveo] | 1            | 19+                    | 157.35        |
| <b>Meningococcal Serogroup B (MenB)</b>                     |                 |   |              |                        |               |
| 90620   |                 | Meningococcus recombinant protein for injection into muscle, 2 dose schedule (MenB-4C) [Bexsero]  | 1            | 10-18                  | 0.00          |
| 90620   | HA              | Meningococcus recombinant protein for injection into muscle, 2 dose schedule (MenB-4C) [Bexsero]  | 1            | 19+                    | 223.75        |
| 90621   |                 | Meningococcus lipoprotein for injection into muscle, 2 or 3 dose schedule (MenB-FHbp) [Trumenba]  | 1            | 10-18                  | 0.00          |
| 90621   | HA              | Meningococcus lipoprotein for injection into muscle, 2 or 3 dose schedule (MenB-FHbp) [Trumenba]  | 1            | 19+                    | 190.26        |
| <b>Meningococcal and Haemophilus Influenzae (Hib-MenCY)</b> |                 |   |              |                        |               |
| 90644   |                 | Meningococcal and Haemophilus influenzae B (4 dose schedule) injection into muscle, children 6 weeks-18 months of age (Hib-MenCY)   | 1            | 0-2                    | 0.00          |
| <b>ZOSTER RECOMBINANT (RZV)</b>                             |                 |   |              |                        |               |
| 90750   |                 | Zoster Vaccine (HZC) recombinant, intramuscular [SHINGRIX]  | 1            | 18+                    | 197.90        |
| <b>RABIES</b>   |                 |   |              |                        |               |
| 90375   |                 | Rabies immune globulin for injection beneath skin and/or into muscle [HyperRAB]   | 9            |                        | 285.65        |
| 90376   |                 | Rabies immune globulin for injection beneath skin and/or into muscle, heat treated [Imogam Rabies - HT]   | 9            |                        | 479.72        |
| 90675   |                 | Rabies vaccine, intramuscular [Imovax Rabies; RabAvert]   | 1            |                        | 322.77        |
| <b>RESPIRATORY SYNCYTIAL VIRUS</b>                          |                 |   |              |                        |               |
| 90380   |                 | Respiratory Syncytial Virus monoclonal antibody, seasonal dose; 0.5ml dosage for IM use (BEYFORTUS)^  | 1            | 0-1                    | 0.00          |
| 90381   |                 | Respiratory Syncytial Virus monoclonal antibody, seasonal dose; 1ml dosage for IM use (BEYFORTUS)^  | 1            | 0-1                    | 0.00          |
| 90381   |                 | Respiratory Syncytial Virus monoclonal antibody, seasonal dose; 1ml dosage for IM use (BEYFORTUS)^  | 2            | 1-2                    | 0.00          |
| 96380   |                 | Administration of Respiratory Syncytial Virus monoclonal antibody, seasonal dose, intramuscular, with counseling^   | 1            | 0-2                    | 10.00         |
| 96381   |                 | Administration of Respiratory Syncytial Virus monoclonal antibody, seasonal dose, intramuscular^  | 1            | 0-2                    | 10.00         |
| 90678   |                 | Respiratory Syncytial Virus vaccine, Bivalent, 0.5ml for IM use [ABRYSVO]   | 1            | 10-18 (PREGNANCY ONLY) | 295.00        |

**PRESCRIBED DRUGS IMMUNIZATION FEE SCHEDULE**

**EFFECTIVE: JANUARY 1, 2024**

| <b>CPT Code</b>                                    | <b>Modifier</b> | <b>Description</b>  | <b>Units</b> | <b>Age (Years)</b>        | <b>MaxFee</b> |
|--|-----------------|---|--------------|---------------------------|---------------|
| 90678  | HA              | Respiratory Syncytial Virus vaccine, Bivalent, 0.5ml for IM use [ABRYSVO]   | 1            | 19-59<br>(PREGNANCY ONLY) | 295.00        |
| 90678  | HA              | Respiratory Syncytial Virus vaccine, Bivalent, 0.5ml for IM use [ABRYSVO]   | 1            | 60+                       | 295.00        |
| 90679  |                 | Respiratory Syncytial Virus vaccine, for IM use [AREXVY]  | 1            | 60+                       | 280.00        |
| 90683  |                 | Respiratory syncytial virus vaccine, mRNA lipid nanoparticles, for intramuscular use [mRESVIA]  | 1            | 60+                       | 290.00        |
| <b>COVID-19 VACCINE &amp; ADMINISTRATION CODES</b> |                 |   |              |                           |               |
| 90480  |                 | Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, single dose (all manufacturers)*                                       | 1            | ANY                       | 40.00         |
| 91304  |                 | Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, recombinant spike protein nanoparticle, saponin-based adjuvant, preservative free, 0.5mL dosage, for intramuscular use (Novavax) | 1            | 12-18                     | 0.00          |
| 91304  | HA              | Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, recombinant spike protein nanoparticle, saponin-based adjuvant, preservative free, 0.5mL dosage, for intramuscular use (Novavax) | 1            | 19+                       | 148.20        |
| 91318  |                 | Severe acute respiratory coronavirus 2 (SARS-CoV-2-) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, 0.3 mL dosage, diluent reconstituted, tris-sucrose formulation, for intramuscular use (Pfizer)*                 | 1            | 6MO-4YRS                  | 0.00          |
| 91319  |                 | Severe acute respiratory coronavirus 2 (SARS-CoV-2-) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, 0.3 mL dosage, diluent reconstituted, tris-sucrose formulation, for intramuscular use (Pfizer)*                 | 1            | 5-11YRS                   | 0.00          |
| 91320  |                 | Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, 0.3 mL dosage, tris-sucrose formulation, for intramuscular use (Pfizer)*                                | 1            | 12-18                     | 0.00          |
| 91320  | HA              | Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, 0.3 mL dosage, tris-sucrose formulation, for intramuscular use (Pfizer)*                                | 1            | 19+                       | 131.10        |
| 91321  |                 | Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, 0.25 mL dosage, for intramuscular use (Moderna)*   | 1            | 6MO-11YRS                 | 0.00          |
| 91322  |                 | Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, 0.5 mL dosage, for intramuscular use (Moderna)*  | 1            | 12-18                     | 0.00          |
| 91322  | HA              | Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, 0.5 mL dosage, for intramuscular use (Moderna)*  | 1            | 19+                       | 145.92        |